South Korea Antihypertensive Medicine Sales is set to reach $34.6 Million by 2027 from $32.2 Million, will rise 2.1% per year. Italy, Spain and Australia respectively ranked numbers 2, 3 and 4 in this ranking.
Our readers also like:
Forecast: Renin-Angiotensin System Medicine Sales in South Korea
- Million South Korean Wons
- 2024 to 2028
- ReportLinker Research
Forecast: Antihypertensive Medicine Use in South Korea
- Units (Defined Daily Dosage) Per Thousand Persons Per Day
- 2024 to 2028
- ReportLinker Research
Forecast: Antihypertensive Medicine Sales in South Korea
- US Dollars Per Capita
- 2024 to 2028
- ReportLinker Research
Forecast: Renin-Angiotensin System Medicine Sales in South Korea
- US Dollars PPP Per Capita
- 2024 to 2028
- ReportLinker Research
Forecast: Antihypertensive Medicine Sales in South Korea
- Million South Korean Wons
- 2024 to 2028
- ReportLinker Research
Forecast: Antihypertensive Medicine Sales in South Korea
- US Dollars PPP Per Capita
- 2024 to 2028
- ReportLinker Research
Forecast: Renin-Angiotensin System Medicine Sales in South Korea
- US Dollars Per Capita
- 2024 to 2028
- ReportLinker Research
Forecast: Antihypertensive Medicine Sales in South Korea
- Percent of Total Sales
- 2024 to 2028
- ReportLinker Research
Forecast: Antihypertensive Medicine Sales in South Korea
- Million US Dollars PPP
- 2024 to 2028
- ReportLinker Research
Forecast: Renin-Angiotensin System Medicine Sales in South Korea
- Million US Dollars PPP
- 2024 to 2028
- ReportLinker Research
